A recent decision to allow pharmaceutical companies to circulate pee-reviewd papers about off-label uses of a company’s products is a bad idea that makes one wonder who’s payroll is the FDA on. Ours or the pharmaceutical industries?
The problem with this idea is that the companies can now go after getting FDA approval for very narrow uses and then promote the drugs for more profitable uses without having to go through stringent testing and scrutiny. My understanding is that the FDA is supposed to protect the public, not the interests of the drug industry. This ruling does the exact opposite and Congress needs to step in which it is now in the process of doing, I hope.